Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.
Insulin receptor (IR) overexpression is common in cancers, with expression of the A isoform (IR-A, exon 11-) predominating over the B isoform. The IR-A signals a proliferative, antiapoptotic response to IGF-II, which itself can be secreted by tumors to establish an autocrine proliferative loop. Ther...
Main Authors: | Brierley, G, Macaulay, S, Forbes, B, Wallace, J, Cosgrove, L, Macaulay, V |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
Targeting the IGF receptor as treatment for cancer
by: Macaulay, V
Published: (2007) -
The IGF receptor as anticancer treatment target.
by: Macaulay, V
Published: (2004) -
Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
by: Riedemann, J, et al.
Published: (2007) -
Assessment of androgen receptor, IGF-IR and insulin receptor expression in male patients with severe peripheral artery disease
by: Michele Andreucci, et al.
Published: (2022-01-01) -
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
by: Macaulay, V, et al.
Published: (2010)